Cytokinetics Posts Cohort 3 Data From Aficamten Trial In Heart Disease Patients


Cytokinetics Incorporated CYTK has announced topline results from Cohort 3 of REDWOOD-HCM Phase 2 trial of aficamten for hypertrophic cardiomyopathy (HCM) in which the heart muscle (myocardium) becomes abnormally thick.

  • Cohort 3 data showed substantial reductions in the average resting left ventricular outflow tract gradient (LVOT-G), and the post-Valsalva LVOT-G were achieved. 
  • These clinically relevant decreases in pressure gradients were achieved with only modest reductions in average left ventricular ejection fraction (LVEF).
  • There were no patients whose LVEF fell below the prespecified safety threshold of 50%. 
  • We look forward to initiating screening of patients in SEQUOIA-HCM soon and look forward to sharing these results from Cohort 3 with the medical community in April."
  • Aficamten is an investigational selective, small molecule cardiac myosin inhibitor. It is designed to reduce the number of active actin-myosin cross-bridges during each cardiac cycle and consequently suppress myocardial hypercontractility.
  • The Company is conducting a SEQUOIA-HCM Phase 3 trial in patients who have exhausted other available medical therapies.
  • Price Action: CYTK shares are down 3.43% at $32.05 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!